PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis

BACKGROUND: PD-1/PD-L1 immune checkpoint inhibitors (ICIs) have been controversial in the treatment of metastatic triple negative breast cancer (mTNBC). We collected randomized controlled trials in accordance with the study and carried out meta-analysis to comprehensively evaluate the efficacy and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yinan, Jin, Xueying, Zhu, Xiaoling, Xu, Yan, Si, Wei, Zhao, Jianguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292799/
https://www.ncbi.nlm.nih.gov/pubmed/37377959
http://dx.doi.org/10.3389/fimmu.2023.1206689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292799/
https://www.ncbi.nlm.nih.gov/pubmed/37377959
http://dx.doi.org/10.3389/fimmu.2023.1206689

Ejemplares similares